Research record

Publications & patents.

Peer-reviewed papers, book chapters, preprints and patent applications from 2002 onward — B-cell epitope prediction and machine learning, computational vaccinology, systems biology and drug repositioning, and most recently engineered lytic proteins. The complete record, not a selection.

14
Peer-reviewed papers
& book chapters
1
Preprint under
journal review
3
Patent
applications

Preprints & work in press

  • 2026
    Multi-dimensional optimization of a lysin towards a ribolysin against life-threatening S. aureus infections: Fc-LysM-CHAP and its strong synergy with standard-of-care antibiotics

    Badarau A, Bauer B, Visram Z, Qiao R, Majoros-Hashempour A, Söllner J, Durica-Mitic S, Dunne OM, Kluj R, Kestemont D, Kieninger A-K, Kulig M, Berdaguer R, Schwebs T, Zerbs M, Czermak P, von Freyberg M, Schmidt J, Schmidberger L, Mayer D, Protano M, Miller HA, Palowitch GM, Dulberger CL, Massaro M, Ivanisenko N, Jacomet H, Ngatcha Bakoue D, Oteri F, Sela G, Corsini L.

    bioRxiv 2026.04.27.720530 (v2, 8 May 2026). Submitted to Nature Biotechnology. Preprint

Peer-reviewed articles & book chapters

  • 2026
    Development and validation of an LNA-based multiplex RT-qPCR assay for differentiating Betaarterivirus europensis (PRRSV-1), Betaarterivirus americense (PRRSV-2), and the highly pathogenic L8 lineage of PRRSV-2

    Gyurján I, Sipos-Kozma Z, Ásványi B, Szathmáry M, Kerényi Z, Szenthe K, Söllner J, Szathmary S, Dénes B, Greff B, Varga L, Bánáti F.

    The Veterinary Journal 2026;318:106731.

  • 2016
    Systems Vaccinology: Applications, Trends, and Perspectives

    Söllner J.

    In: Vaccine Design. Methods and Protocols, Vol. 1: Vaccines for Human Diseases. Methods Mol Biol 2016;1403:107–30. Springer. Book chapter

  • 2015
    Computational peptide vaccinology

    Söllner J.

    Methods Mol Biol 2015;1268:291–312. Book chapter

  • 2012
    Synthetic lethality for linking the mycophenolate mofetil mode of action with molecular disease and drug profiles

    Söllner J, Mayer P, Heinzel A, Fechete R, Siehs C, Oberbauer R, Mayer B.

    Molecular BioSystems 2012;8(12):3197–207.

  • 2011
    Beyond epitopes: future and application of computational vaccinology

    Söllner J.

    Human Vaccines 2011;7(7):795–7. Commentary

  • 2011
    Mapping of molecular pathways, biomarkers and drug targets for diabetic nephropathy

    Fechete R, Heinzel A, Perco P, Mönks K, Söllner J, Stelzer G, Eder S, Lancet D, Oberbauer R, Mayer G, Mayer B.

    Proteomics Clinical Applications 2011;5(5–6):354–66.

  • 2010
    Concept and application of a computational vaccinology workflow

    Söllner J, Heinzel A, Summer G, Fechete R, Stipkovits L, Szathmary S, Mayer B.

    Immunome Research 2010;6(Suppl 2):S7.

  • 2008
    Analysis and prediction of protective continuous B-cell epitopes on pathogen proteins

    Sollner J, Grohmann R, Rapberger R, Perco P, Lukas A, Mayer B.

    Immunome Research 2008;4:1.

  • 2008
    Mouse mammary tumor virus integration site selection in human and mouse genomes

    Faschinger A, Rouault F, Sollner J, Lukas A, Salmons B, Günzburg WH, Indik S.

    Journal of Virology 2008;82(3):1360–7.

  • 2007
    Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools

    Greenbaum JA, Andersen PH, Blythe M, Bui HH, Cachau RE, Crowe J, Davies M, Kolaskar AS, Lund O, Morrison S, Mumey B, Ofran Y, Pellequer JL, Pinilla C, Ponomarenko JV, Raghava GP, van Regenmortel MH, Roggen EL, Sette A, Schlessinger A, Sollner J, Zand M, Peters B.

    Journal of Molecular Recognition 2007;20(2):75–82. Community consensus

  • 2006
    Selection and combination of machine learning classifiers for prediction of linear B-cell epitopes on proteins

    Söllner J.

    Journal of Molecular Recognition 2006;19(3):209–14.

  • 2006
    Machine learning approaches for prediction of linear B-cell epitopes on proteins

    Söllner J, Mayer B.

    Journal of Molecular Recognition 2006;19(3):200–8.

  • 2003
    Functional selection of vaccine candidate peptides from Staphylococcus aureus whole-genome expression libraries in vitro

    Weichhart T, Horky M, Söllner J, Gangl S, Henics T, Nagy E, Meinke A, von Gabain A, Fraser CM, Gill SR, Hafner M, von Ahsen U.

    Infection and Immunity 2003;71(8):4633–41.

  • 2002
    Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus

    Etz H, Minh DB, Henics T, Dryla A, Winkler B, Triska C, Boyd AP, Söllner J, Schmidt W, von Ahsen U, Buschle M, Gill SR, Kolonay J, Khalak H, Fraser CM, von Gabain A, Nagy E, Meinke A.

    Proceedings of the National Academy of Sciences USA 2002;99(10):6573–8.

Patent applications

Three international (PCT) applications as co-inventor, filed by the respective employers. Publication numbers link to the full text on Google Patents.

  • 2021
    Propionibacterium acnes prophylactic and therapeutic immune treatment

    Selak S, Triska C, Schuster M, Söllner J, Roppenser B, Weinhäupl T, Rössler M.

    WO 2021/165543 A1 · Applicant: Origimm Biotechnology GmbH · Filed 22 Feb 2021, published 26 Aug 2021, earliest priority 21 Feb 2020.

  • 2011
    Critical gene targets for cytotoxic therapy

    Lukas A, Soellner J, Bernthaler A, Mayer B, Fechete R, Perco P, Heinzel A.

    WO 2011/144738 A1 · Applicant: emergentec biodevelopment GmbH · Filed 20 May 2011, published 24 Nov 2011.

  • 2003
    S. aureus antigene

    von Ahsen U, Soellner J, Weichhart T, Hafner M.

    WO 2004/013166 A2 · Applicant: Intercell Austria AG · Filed 22 Jul 2003, published 12 Feb 2004.

Open-source projects

Methods I have released publicly under MIT, at github.com/sodatana. Published code is the part of the record you can actually run.

  • Python
    mimotope-maker

    Peptide mimotopes for discontinuous (conformational) epitopes. It works from an ensemble of structures rather than one static model, identifying surface residues that stay close to each other as the protein moves, and proposes linear peptides mimicking that surface — ranked, and in L, retro-inverso and chimeric L/D forms. The original in-house Perl pipeline is kept alongside the Python implementation.

  • Python
    cdsbo — mRNA coding sequence bicodon optimization

    Codon optimization that scores adjacent codon pairs instead of single codons, so codon-context effects survive the optimization. A Viterbi dynamic-programming pass finds the globally optimal coding sequence rather than making a greedy per-residue choice, against bicodon tables derived from human tissue-specific proteomics data — swappable for other expression systems. Kozak context and forbidden patterns such as restriction sites are handled explicitly.

  • Python
    LLM-offloader_benchmark

    A test suite for deciding which parts of an AI-assisted coding workflow can be handed to a local model and which cannot. It runs identical graded tasks on a local LLM (Ollama / gemma4) and on a frontier model under the same constraints, scores both deterministically against ground truth, and pairs quality with token cost into a per-task offload verdict. The motivation is practical: keep sensitive work on-device, and spend frontier-model budget where it changes the answer.

What the record is about

Four threads run through twenty-plus years of it, and all four are still live in client work:

  • Epitopes and the machine learning around them — the PhD work at Intercell (PNAS 2002, Infect Immun 2003) and the methodological papers that followed (J Mol Recognit 2006 ×2, Immunome Res 2008), including the community benchmarking consensus (J Mol Recognit 2007). This is the foundation under today's epitope prediction and antigen selection work.
  • Computational vaccinology as a workflow — not a single prediction but a pipeline with defensible decision points: Immunome Res 2010, Hum Vaccin 2011, and the two Methods in Molecular Biology chapters (2015, 2016) that document the method end to end.
  • Systems biology, biomarkers and drug repositioning — protein/drug/disease networks applied to therapy selection and target triage: Proteomics Clin Appl 2011, Mol Biosyst 2012, and the cytotoxic-target patent.
  • Engineered proteins against hard infections — the current thread: multi-parameter optimization of a lysin into a Fc-fused ribolysin against S. aureus (bioRxiv 2026), and molecular diagnostics for veterinary pathogens (Vet J 2026).

If a prospective project sits near any of these, there is published method behind the advice — and where there is not, I will say so.

Start a conversation →